Core Viewpoint - Watson Bio has signed a strategic cooperation framework agreement with Yuxi State-owned Capital Operation Co., Ltd. to establish a long-term and comprehensive partnership in the vaccine and bioproducts industry, aiming to enhance industrial upgrading and business expansion in innovative vaccines and synthetic biological manufacturing over a three-year period [1][3]. Group 1: Strategic Cooperation - The strategic cooperation aims to leverage both parties' high-quality industrial resources to deepen collaboration in various aspects such as industrial resources, layout, and implementation [1][3]. - Yuxi Operation Company will engage in capital operations through methods such as subscribing to the company's shares, participating in fund investments, and industry mergers and acquisitions to support Watson Bio in optimizing its equity structure and enhancing capital strength [1][3]. Group 2: Company Profile - Watson Bio is a high-tech biopharmaceutical company focused on the research, development, production, and sales of human vaccines, aiming to become a leading and sustainable international vaccine manufacturer [2]. - The company has become the most competitive in China in terms of the number and variety of independently developed vaccine products, with its vaccines exported to 22 countries and regions [2]. - Watson Bio is the first in China and the second globally to independently develop and successfully launch a 13-valent pneumonia conjugate vaccine, maintaining the largest market share in China since 2021 [2].